All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F21%3AA2202CTD" target="_blank" >RIV/61988987:17110/21:A2202CTD - isvavai.cz</a>

  • Alternative codes found

    RIV/00843989:_____/21:E0109006 RIV/00216208:11110/21:10438210 RIV/65269705:_____/21:00074360 RIV/00064165:_____/21:10438210

  • Result on the web

    <a href="https://www.webofscience.com/wos/woscc/full-record/WOS:000646325700001?SID=D1v41LNKnqSuWlaZyU6" target="_blank" >https://www.webofscience.com/wos/woscc/full-record/WOS:000646325700001?SID=D1v41LNKnqSuWlaZyU6</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1002/ajh.26172" target="_blank" >10.1002/ajh.26172</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

  • Original language description

    Elderly and frail patients with multiple myeloma (MM) are more vulnerable to the toxicity of combination therapies, often resulting in treatment modifications and suboptimal outcomes. The phase 3 BOSTON study showed that once-weekly selinexor and bortezomib with low-dose dexamethasone (XVd) improved PFS and ORR compared with standard twice-weekly bortezomib and moderate-dose dexamethasone (Vd) in patients with previously treated MM. This is a retrospective subgroup analysis of the multicenter, prospective, randomized BOSTON trial. Post hoc analyses were performed to compare XVd versus Vd safety and efficacy according to age and frailty status (<65 and >= 65 years, nonfrail and frail). Patients >= 65 years with XVd had higher ORR (OR 1.77, p = .024), >= VGPR (OR, 1.68, p = .027), PFS (HR 0.55, p = .002), and improved OS (HR 0.63, p = .030), compared with Vd. In frail patients, XVd was associated with a trend towards better PFS (HR 0.69, p = .08) and OS (HR 0.62, p = .062). Significant improvements were also observed in patients <65 (ORR and TTNT) and nonfrail patients (PFS, ORR, >= VGPR, and TTNT). Patients treated with XVd had a lower incidence of grade >= 2 peripheral neuropathy in >= 65 year-old (22% vs. 37%; p = .0060) and frail patients (15% vs. 44%; p = .0002). Grade >= 3 TEAEs were not observed more often in older compared to younger patients, nor in frail compared to nonfrail patients. XVd is safe and effective in patients <65 and >= 65 and in nonfrail and frail patients with previously treated MM.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30205 - Hematology

Result continuities

  • Project

  • Continuities

    V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Others

  • Publication year

    2021

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    American Journal of Hematology

  • ISSN

    0361-8609

  • e-ISSN

  • Volume of the periodical

    96

  • Issue of the periodical within the volume

    6

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    11

  • Pages from-to

    708-718

  • UT code for WoS article

    000646325700001

  • EID of the result in the Scopus database